Abivax’s U.S.-listed ADS are lower in the latest session, with price action consistent with de-risking and profit-taking rather than a single fresh headline. The company’s most recent major update was released on March 23, 2026 (full-year 2025 results and business update), and the next widely telegraphed catalyst is Phase 3 ABTECT-UC maintenance topline data expected in late Q2 2026—leaving the stock vulnerable to swings as positioning resets between catalysts. (ir.abivax.com)

Abivax’s valuation and momentum are tightly linked to obefazimod in ulcerative colitis, with management reiterating that the pivotal maintenance trial remains on track for a late-Q2 2026 readout. Until that data arrives, day-to-day moves can be amplified by technical trading and event-driven positioning, especially after the stock’s large prior run tied to Phase 3 induction success. (finance.yahoo.com)

Separately, filings and screens point to potential periodic selling pressure from existing holders: one notable Rule 144 notice referenced a proposed sale covering 1,000,000 ADS by a major shareholder (Sofinnova Crossover I SLP), which can weigh on sentiment even when it is not executed immediately. Market participants will also watch short interest levels and borrow conditions as the late-Q2 catalyst approaches. (stocktitan.net)

The key swing factor for ABVX remains the ABTECT maintenance topline results expected in late Q2 2026, which management has framed as important for demonstrating durability of response and supporting regulatory plans. Investors will also track any interim safety monitoring updates, cash burn commentary, and any additional shareholder selling signals as the company moves toward its next clinical milestone. (finance.yahoo.com)